Female cancer survivors more likely to report cost-related non-adherence

Share this content:

the ONA take:

Significant gender differences in cost-related medication non-adherence (CRN) were found among cancer survivors after adjusting for differences in sociodemographic, health status, and insurance coverage, a new study published online ahead of print in the Journal of Cancer Survivorship.

Because it has been reported that cancer survivors delay or avoid necessary care due to costs, researchers sought to determine the prevalence of CRN by gender and other factors among cancer survivors.

For the study, researchers from the University of South Carolina Arnold School of Public Health, in Columbia, analyzed data from 15,159 cancer survivors. Of those, 7.4% of male and 12.5% of female survivors reported CRN.

Results showed that female cancer survivors were 27% more likely than males to report CRN. Researchers found that a higher number of comorbidities and activity limitations were associated with higher CRN rates for both males and females.

“Given the rapid increase in prescription drug costs, it is important to monitor closely the CRN in high-risk subgroups,” the authors conclude.

Are oncology nurses prepared to discuss fertility matters?
Significant gender differences in cost-related medication non-adherence were found among cancer survivors.
It has been reported that cancer survivors are delaying or avoiding necessary care due to costs. Medication non-adherence is one of the important aspects of deferred treatment. This study estimates the prevalence of cost-related medication non-adherence (CRN) by gender and factors associated with CRN among cancer survivors.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs